Aquestive Therapeutics, Inc. (AQST) P/E Ratio History
Historical price-to-earnings valuation from 2023 to 2023
Loading P/E history...
AQST Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Aquestive Therapeutics, Inc. (AQST) trades at a price-to-earnings ratio of -5.6x, with a stock price of $4.23 and trailing twelve-month earnings per share of $-0.69.
The current P/E is 102% below its 5-year average of 237.6x. Over the past five years, AQST's P/E has ranged from a low of 237.6x to a high of 237.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, AQST trades at a 125% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, AQST trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AQST DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
AQST P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.9Lowest | 0.67Best | +817% | |
| $1B | 22.7 | 1.27 | -7% | |
| $2B | 36.3 | 4.85 | +1883%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
AQST Historical P/E Data (2023–2023)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $2.02 | $0.01 | 237.6x | +0% |
Average P/E for displayed period: 237.6x
See AQST's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AQST Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AQST vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAQST — Frequently Asked Questions
Quick answers to the most common questions about buying AQST stock.
Is AQST stock overvalued or undervalued?
AQST trades at -5.6x P/E, below its 5-year average of 237.6x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does AQST's valuation compare to peers?
Aquestive Therapeutics, Inc. P/E of -5.6x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is AQST's PEG ratio?
AQST PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2023-2023.